Monitor upcoming data readouts in 2H 2026 (EIK1001 NSCLC Phase 2 data, EIK1003 Phase 1/2 data, EIK1005 initial data) as potential catalysts. The presentation indicates continued clinical execution but no near-term inflection point.
Price Chart
Executive Summary
Eikon Therapeutics filed an 8-K on August 13, 2026, furnishing an updated corporate presentation (Exhibit 99.1) that highlights encouraging clinical data across its pipeline, including EIK1001 (TLR7/8) in NSCLC with a 63.1% ORR and EIK1003 (PARP1) showing a 14.3% monotherapy ORR. The presentation outlines upcoming milestones such as interim analyses for the melanoma registrational trial (2H 2026) and Phase 2 NSCLC data readouts (2H 2026). This is a routine FD disclosure with no new financial data or material changes, providing a pipeline progress update.
Key Facts
- EIK1001 TeLuRide-005 study in NSCLC: ORR 63.1%, DCR 90.8%, median DOR >11 months (data as of May 4, 2026).
- EIK1003 monotherapy ORR 14.3% in solid tumors; combination with paclitaxel ORR 24.5%.
- EIK1005 WRN inhibitor clinical program initiated; starting dose of 50mg established for Phase 2 trial.
- Upcoming milestones: First interim analysis for melanoma study (2H 2026), second interim analysis (1H 2027), Phase 2 NSCLC data readout (2H 2026), first patient dosed in NSCLC registration trial (2H 2026).
- No financial data or guidance provided in the filing.
Financial Impact
No financial figures reported; routine corporate presentation update.
Risk Factors
- Clinical trial risks: potential for negative data in upcoming readouts.
- No revenue or profitability timeline provided; company is pre-revenue.
- Competitive landscape in PARP1 and TLR7/8 space.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-349936 |
| Document: eikn-ex99_1.htm | 0001193125-26-349936 |
| Document: 0001193125-26-349936-index-headers.html | 0001193125-26-349936 |
| Document: 0001193125-26-349936-index.html | 0001193125-26-349936 |
| Document: 0001193125-26-349936.txt | 0001193125-26-349936 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 26, 2026 today | Press Release | $7.48 | awaiting T+20 | — | $6.68 (−10.66%) |
Oct 23, 2026 3d ago | 8-K | $8.01 | awaiting T+20 | — | $6.68 (−16.57%) |
Oct 7, 2026 18d ago | SC 13G/A | $7.54 | awaiting T+20 | — | $6.68 (−11.37%) |
Oct 2, 2026 23d ago | SC 13G/A | $7.33 | awaiting T+20 | — | $6.68 (−8.83%) |
Sep 22, 2026 4w ago | Institutional Cluster | $8.98 $8.18 | ▼ −8.91% | ▼ −8.35% | $6.68 (−25.58%) |
Sep 8, 2026 6w ago | Insider Buy | $10.73 $7.54 | ▼ −29.73% | ▼ −31.67% | $6.68 (−37.72%) |
Sep 3, 2026 7w ago | Press Release | $10.96 $8.04 | ▼ −26.64% | ▼ −25.52% | $6.68 (−39.03%) |
Aug 13, 2026 10w ago | 8-K | $11.05 $9.36 | ▼ −15.29% | ▼ −13.30% | $6.68 (−39.52%) |
Jul 20, 2026 14w ago | Press Release | $9.65 $10.47 | ▲ +8.50% | ▲ +4.38% | $6.68 (−30.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers